Compare ATNM & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATNM | NEPH |
|---|---|---|
| Founded | 2000 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.2M | 60.0M |
| IPO Year | N/A | 2004 |
| Metric | ATNM | NEPH |
|---|---|---|
| Price | $1.58 | $4.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $4.00 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 224.5K | 75.2K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | $90,000.00 | ★ $17,930,000.00 |
| Revenue This Year | N/A | $33.32 |
| Revenue Next Year | $42,943.57 | $12.27 |
| P/E Ratio | ★ N/A | $36.15 |
| Revenue Growth | 11.11 | ★ 32.36 |
| 52 Week Low | $1.03 | $1.39 |
| 52 Week High | $2.41 | $6.42 |
| Indicator | ATNM | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 65.07 | 47.81 |
| Support Level | $1.37 | $4.83 |
| Resistance Level | $1.54 | $5.97 |
| Average True Range (ATR) | 0.08 | 0.62 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 72.95 | 26.90 |
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.